Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lacutamab · IPH-4102

Monoclonal antibody · Kills target cells, directed at killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) · developed by Innate Pharma

Phase 2 Most advanced trial
IPHA Developer
2 Registered trials

What is Lacutamab?

Lacutamab is a humanized monoclonal antibody that binds KIR3DL2, a receptor expressed on certain tumor cells, including most subtypes of cutaneous T-cell lymphoma. It recruits natural killer cells and induces antibody-dependent cellular cytotoxicity to lyse KIR3DL2-expressing cells. It is studied in T-cell lymphomas, including mycosis fungoides and Sezary syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IPH-4102
Drug type
Monoclonal antibody
Targets
killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2)
Mechanism
Kills target cells, directed at killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2)
Pathways
NK cell-mediated cytotoxicity, antibody-dependent cellular cytotoxicity
Therapy area
Oncology
Developer
Innate Pharma (IPHA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
N8O7MY0VNS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04984837 Phase 2 Peripheral T Cell Lymphoma Active not recruiting IPHA
NCT03902184 Phase 2 Lymphoma, T-Cell Completed IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Peripheral T Cell LymphomaRelapse/RecurrenceLymphoma, T-CellLymphoma, T-Cell, CutaneousMycosis Fungoides/Sezary Syndrome

More from Innate Pharma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.

Follow IPHA, the company behind Lacutamab

See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPHA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.